Taking
nature’s lead in antimicrobials

 
21/03/2017

NovaBiotics Chief Executive Addresses 'Superbugs & Superdrugs' Conference on Antimicrobial Drug Discovery

 

21 March 2017, London: Dr Deborah O’Neil, Chief Executive and Scientific Officer of Novabiotics, the clinical-stage anti-infectives biotechnology company, this morning will address the audience of ‘Superbugs & Superdrugs – A Focus on Antimicrobials’, presenting Novabiotics’ antimicrobial peptide platform and its role in the fight against antimicrobial resistance (AMR).

AMR is now one of the greatest threats to human health and is firmly on the global agenda. All 193 UN member states committed to combating the proliferation of antibiotic resistance in September 2016, while last month, WHO published a global priority list of antibiotic resistant bacteria, the first list of its kind.

Antimicrobial peptides (AMP) are one solution to the urgent need for new classes of anti-infective therapies.  Intelligent drug design of novel peptide antibiotics and antifungals has significant potential in addressing a range of clinically challenging infections.

Dr Deborah O’Neil said: “Novabiotics is at the forefront of the antimicrobial drug discovery process; we are designing new molecules with new therapeutic applications to tackle these very real threats. We’ve gone back to the drawing board to develop two therapeutic platforms and a range of novel drug candidate antimicrobials with the aim of tackling antimicrobial resistance.

“AMR has been acknowledged as a significant growing threat among the scientific community for decades. The recent commitment from governments and health organisations marks a step forward in the fight against AMR.  There is much to be done.”